



Press Release

Dr. Robert Knerr to succeed Wolter Kuizinga as Head of Business Development at the STADA Group

Bad Vilbel, April 16, 2018 – Dr. Robert Knerr (41) is the new Executive Vice President of Global Business Development for the STADA Group. He will be taking up this position as of September 1, at latest, succeeding Wolter Kuizinga who has been performing the role on an interim basis. Knerr will report directly to CEO Dr. Claudio Albrecht.

"I would like to thank Wolter Kuizinga for having managed this extremely important key position for STADA since September 2017 with foresight and for implementing some key changes for the future. It was always clear from the outset that Wolter would only be working for STADA on an interim basis. Robert Knerr has emerged as the ideal successor in this transitional phase. This appointment underscores our approach of filling more key positions at STADA with highly qualified internal candidates going forward," Claudio Albrecht emphasizes. "He is an expert in the field of pharmaceutical technology and is highly familiar with STADA as a company having already held positions here in the past."

"I am very much looking forward to the challenge of supporting STADA's growth strategy for new and existing markets, and I am confident that Business Development will make a significant contribution to achieving the company's goals," said Robert Knerr.

Knerr joined STADA Arzneimittel AG in 2011 as a Personal Consultant to the Director of Production & Development, and since then has filled a number of positions within the company – most recently as the Vice President of Portfolio Management. Prior to this he held various positions of rising seniority at the Aenova Group company Haupt Pharma Amareg GmbH. Studying part-time, Knerr earned his MBA in Pharmaceutical Management at the International School of Management in Dortmund between 2008 and 2010.

Executive Board: Dr. Claudio Albrecht (CEO) / Mark Keatley / Dr. Barthold Piening
Supervisory Board Chairman: Dr. Günter von Au



A licensed pharmacist, Knerr earned his doctorate in Pharmaceutical Technology magna cum laude at the University of Regensburg in 2006, where he also worked as a research assistant. He is married and has two children.

About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de

Or visit us in the Internet at www.stada.com

Executive Board: Dr. Claudio Albrecht (CEO) / Mark Keatley / Dr. Barthold Piening
Supervisory Board Chairman: Dr. Günter von Au